SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

The American College of Physicians (ACP) issued new A1C guidelines for people managing type 2 diabetes, drawing both criticism and praise. Here’s what to know about the new target range and what ...

Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with ...